Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04642469
Title	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)
Acronym	MERMAID-2
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Durvalumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG